Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. A Study On Expression Of Programmed Death Ligand-1 In Small Cell Lung Carcinoma And Correlation With Clinicopathological Parameters.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. A Study On Expression Of Programmed Death Ligand-1 In Small Cell Lung Carcinoma And Correlation With Clinicopathological Parameters.

Related Experiment Video

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K

A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters.

Sudha Sudha1, Saumya Shukla1, Nuzhat Husain1

  • 1Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow-UP, India.

Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists
|May 29, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Programmed death ligand 1 (PD-L1) expression was found in 14% of small cell lung carcinoma (SCLC) cases. This finding may help develop new SCLC treatment strategies to improve patient survival.

Keywords:
programmed death ligand-1.small cell lung carcinomaimmunotherapy

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.1K

Related Experiment Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.1K

Area of Science:

  • Oncology
  • Immunology
  • Pathology

Background:

  • Small cell lung carcinoma (SCLC) exhibits rapid growth and aggressive behavior, leading to a poor prognosis.
  • Current standard therapies offer limited efficacy in managing SCLC progression.

Purpose of the Study:

  • To determine the frequency of programmed death ligand 1 (PD-L1) expression in SCLC.
  • To investigate the correlation between PD-L1 expression and clinico-pathological features in SCLC patients.

Main Methods:

  • Analysis of 100 SCLC cases using the SP263 clone on the Ventana benchmark XT system for PD-L1 testing.
  • Cases with ≥ 1% PD-L1 expression in tumor or immune cells were classified as positive.
  • Tumor Proportion Score (TPS) and Immune Proportion Score (IPS) were calculated using a ≥ 1% cut-off.

Main Results:

  • PD-L1 expression was detected in 14% of SCLC cases (TPS: 10%, IPS: 9.78% at ≥ 1% cut-off).
  • PD-L1 positivity was more prevalent in males over 40 years old and exclusively observed in smokers.
  • Necrosis was significantly more frequent in PD-L1 positive cases (71.4%) compared to the PD-L1 negative subgroup (p = 0.010).

Conclusions:

  • PD-L1 expression is present in a subset of SCLC patients, particularly in smokers and males over 40.
  • The association of PD-L1 expression with necrosis suggests potential clinical relevance.
  • Targeting PD-L1 could represent a novel therapeutic strategy for SCLC, potentially improving patient outcomes.